Home Cart Sign in  
Chemical Structure| 53678-77-6 Chemical Structure| 53678-77-6

Structure of Muramyl dipeptide
CAS No.: 53678-77-6

Chemical Structure| 53678-77-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Muramyl dipeptide, a synthetic immunoreactive peptide, is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide indirectly attenuates osteoclast differentiation through a decreased RANKL/OPG ratio.

Synonyms: MDP; N-Acetylmuramoyl dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Muramyl dipeptide

CAS No. :53678-77-6
Formula : C19H32N4O11
M.W : 492.48
SMILES Code : [C@H]([C@@H](NC(C)=O)C=O)(O[C@@H](C(N[C@H](C(N[C@H](CCC(O)=O)C(N)=O)=O)C)=O)C)[C@@H]([C@@H](CO)O)O
Synonyms :
MDP; N-Acetylmuramoyl dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine
MDL No. :MFCD00077638

Safety of Muramyl dipeptide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Related Pathways of Muramyl dipeptide

MAPK
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
rat costal chondrocytes 0.05-50 μg/ml 72 h No effect on glycosaminoglycan synthesis when used alone, but enhanced the lipopolysaccharide-induced inhibition of glycosaminoglycan synthesis when co-administered with lipopolysaccharide PMC1004952
murine bone marrow-derived dendritic cells 50 μg/ml 24 h To validate the effect of MDP prestimulation in murine BMDCs, showing that NOD2-intact BMDCs exhibited reduced responsiveness to TLR2, TLR4, TLR5, and TLR9 ligands after MDP prestimulation, while NOD2-deficient BMDCs did not. PMC2176188
human monocyte-derived dendritic cells 10 μg/ml 24 h To investigate the effect of MDP prestimulation on subsequent TLR ligand-induced cytokine responses, showing that MDP prestimulation reduced proinflammatory cytokine production (e.g., IL-12p40, IL-6, and CXCL10) in response to multiple TLR ligands. PMC2176188
J774.1 macrophage-like cell line 1 μM 4 h Significantly enhanced the superoxide anion production capacity upon PMA stimulation. PMC2185752
mouse peritoneal macrophages 1 μM overnight Enhanced the ability of macrophages to produce superoxide anion in response to PMA stimulation, with a release twice that of control cells. PMC2185752
Mouse bone marrow-derived macrophages (BMMs) 3 or 10 µg/ml 24 h To evaluate the effect of MDP on SaLTA-induced NO production. Results showed that MDP significantly enhanced SaLTA-induced NO production, and this enhancement was attenuated in BMMs from TLR2-, CD14-, MyD88-, and NOD2-deficient mice. PMC11659290
RAW 264.7 cells 3 or 10 µg/ml 24 h To evaluate the effect of MDP on SaLTA-induced NO production. Results showed that MDP alone did not affect NO production but significantly enhanced SaLTA-induced NO production. PMC11659290
human dental pulp cells (HDPCs) 1-20 µg/mL 14 days MDP significantly inhibited odontoblast differentiation of HDPCs, as shown by reduced ALP activity, decreased expression of odontoblast/osteoblast markers, and diminished mineralized nodule formation. NOD2 siRNA transfection reversed the MDP-downregulated odontoblast differentiation. PMC4293730
THP-1 cells 50 µg/mL 24 h MDP induced a significant dose-dependent increase in IL-6 and TNFα secretion upon re-stimulation with LPS or Pam3Cys, indicating that MDP can induce a trained immunity phenotype. PMC9289449
HEK-Blue™-hNOD2 cells 0.1, 0.2, 0.4, 1, 5, 10 μg/mL 6 h To evaluate the activation of NOD2 receptor by MDP, results showed that MDP's effect is dose-dependent, with the best induction at 8 μg/mL. PMC9321587

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice TNBS-induced colitis Intraperitoneal injection 100 μg 3 consecutive days (days –3 to –1) To evaluate the protective effect of MDP pretreatment on TNBS colitis, showing that MDP pretreatment significantly reduced weight loss and histopathological damage and decreased cytokine responses to multiple TLR ligands in MLN and colonic LP cells. PMC2176188
Mice Mouse model of Alzheimer's disease Intraperitoneal injection 10 mg/kg High frequency (2 times/week over 6 months) and low frequency (once a week over 3 months) To evaluate the effects of MDP on cognitive function in a mouse model of Alzheimer's disease. Results showed that MDP improved memory function, increased expression of synaptic plasticity marker PSD95 and Aβ clearance protein LRP1, increased monocyte chemoattractant protein-1 (MCP-1) levels, decreased intercellular adhesion molecule-1 (ICAM-1) levels, but did not alter microglial marker Iba1 expression. PMC7376735
Mice APP swe/PS1 mouse model Intraperitoneal injection 10 mg/kg Once daily for 3 consecutive days, then once a week for 3 months To study the effect of MDP on cognitive decline and Alzheimer's disease pathology in APP swe/PS1 mice. Results showed that MDP injections delayed cognitive decline, protected the blood-brain barrier, and reduced amyloid load through different mechanisms in different sexes. PMC9321587

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.15mL

2.03mL

1.02mL

20.31mL

4.06mL

2.03mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories